A study to learn more about how drugs that switch off oestrogen affect breast cancer cells (FemarA)
Cancer type:
Status:
Phase:
This study looked at tissue samples to compare the effects of drugs called anastrozole (Arimidex) and letrozole (Femara) on breast cancer cells.
Anastrozole and letrozole are both aromatase inhibitors. These are a type of hormone therapy that doctors often prescribe for women with breast cancer who have been though the
This study was to learn more about the effects of letrozole and anastrozole on cancer cells. The women taking part had either letrozole or anastrozole for 2 weeks before their planned breast cancer surgery.
The researchers studied breast tissue that had been removed when the women had a biopsy to diagnose breast cancer, and compared them with tissue removed during surgery. They looked at how the drug affected the cancer cells and healthy breast tissue. They then compared the results from each drug.
The aim of this study was to see how each drug affected the growth of breast cancer cells.
Summary of results
The study team found there was no difference between anastrozole and letrozole.
This was a phase 3 study. It recruited 206 women.
The researchers were able to look at 209 tissue samples
- 103 from the women who had anastrozole (2 of the women had cancer in both breasts)
- 106 from those who had letrozole (1 woman had cancer in both breasts)
The researchers looked at the levels of substances (
They then compared the results between anastrozole and letrozole. They found no significant difference between the 2 drugs.
The researchers also looked at how anastrozole and letrozole affected the growth of breast cancer cells that had receptors for the hormones
The trial team concluded that there was no difference between anastrozole and letrozole.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor JM Dixon
Supported by
Experimental Cancer Medicine Centre (ECMC)
Novartis
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040